touchFEATURE
NSCLC disease awareness: unmet needs and diagnostic testing in EGFR-mutated NSCLC
Learning Objectives
After watching this activity, participants should be better able to:
- Recognise the current unmet need in patients with advanced EGFRm NSCLC in the second-line setting and describe the mechanisms that underline disease progression despite TKI therapy.
- Describe the relevance of MET signalling in patients with EGFRm NSCLC and the importance of MET diagnostic testing.
- Highlight the underserved non-oncogene-addicted NSCLC population and provide an overview of emerging treatment modalities.
Overview
EGFR tyrosine kinase inhibitors (EGFR-TKIs) are the current standard-of-care first-line treatment for advanced EGFRm NSCLC. However, many patients ultimately undergo disease progression despite EGFR-TKI therapy1, and second-line treatment options are limited. In this series of three engaging videos, watch four leading oncology experts discuss the current unmet need in EGFRm NSCLC,1 the importance of MET diagnostic testing in TKI-resistant disease,2,3 and emerging treatment options for non-oncogene-addicted NSCLC.4
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
